Badanie skuteczności BI 3032950 u pacjentów z umiarkowaną do ciężkiej postacią wrzodziejącego zapalenia jelita grubego

Ulcerative colitis is a condition that causes inflammation and sores in the lining of the large intestine. This study is focused on testing a new treatment called BI 3032950 for people with moderate to severe ulcerative colitis. The treatment involves using a solution that is given either through a vein (intravenous) or under the skin (subcutaneous). The main goal of the study is to see if BI 3032950 can help patients achieve clinical remission, which means reducing the symptoms of the disease, by the 12th week of treatment.

The study will start with an initial phase where the treatment is given intravenously, followed by a maintenance phase where it is given subcutaneously. Participants will be monitored for their response to the treatment, including any changes in symptoms and any side effects they might experience. The study will also look at other outcomes, such as improvements seen during an endoscopy, which is a procedure that allows doctors to look inside the colon.

The study is designed to last up to 104 weeks, with the main focus on the first 12 weeks to assess the initial effectiveness of the treatment. Participants will be closely observed to ensure their safety and to gather information on how well the treatment works in managing ulcerative colitis symptoms. The study aims to provide new insights into the potential benefits of BI 3032950 for people living with this condition.